Bio-Rad Laboratories Statistics
Total Valuation
BIO.B has a market cap or net worth of $10.31 billion. The enterprise value is $10.06 billion.
| Market Cap | 10.31B |
| Enterprise Value | 10.06B |
Important Dates
The last earnings date was Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO.B has 26.74 million shares outstanding. The number of shares has decreased by -3.11% in one year.
| Current Share Class | 5.06M |
| Shares Outstanding | 26.74M |
| Shares Change (YoY) | -3.11% |
| Shares Change (QoQ) | -0.53% |
| Owned by Insiders (%) | 6.53% |
| Owned by Institutions (%) | 73.62% |
| Float | 20.89M |
Valuation Ratios
The trailing PE ratio is 46.35 and the forward PE ratio is 37.40.
| PE Ratio | 46.35 |
| Forward PE | 37.40 |
| PS Ratio | 3.98 |
| Forward PS | 3.94 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | 29.20 |
| P/OCF Ratio | 20.93 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 22.81, with an EV/FCF ratio of 28.49.
| EV / Earnings | 45.24 |
| EV / Sales | 3.89 |
| EV / EBITDA | 22.81 |
| EV / EBIT | 36.95 |
| EV / FCF | 28.49 |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.14 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 3.88 |
| Interest Coverage | 5.58 |
Financial Efficiency
Return on equity (ROE) is 3.11% and return on invested capital (ROIC) is 2.54%.
| Return on Equity (ROE) | 3.11% |
| Return on Assets (ROA) | 1.66% |
| Return on Invested Capital (ROIC) | 2.54% |
| Return on Capital Employed (ROCE) | 2.93% |
| Weighted Average Cost of Capital (WACC) | 9.10% |
| Revenue Per Employee | $347,557 |
| Profits Per Employee | $29,852 |
| Employee Count | 7,450 |
| Asset Turnover | 0.25 |
| Inventory Turnover | 1.57 |
Taxes
In the past 12 months, BIO.B has paid $128.00 million in taxes.
| Income Tax | 128.00M |
| Effective Tax Rate | 36.53% |
Stock Price Statistics
The stock price has increased by +60.36% in the last 52 weeks. The beta is 1.05, so BIO.B's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +60.36% |
| 50-Day Moving Average | 293.98 |
| 200-Day Moving Average | 467.97 |
| Relative Strength Index (RSI) | 69.62 |
| Average Volume (20 Days) | 394 |
Short Selling Information
The latest short interest is 14, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 14 |
| Short Previous Month | 14 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.16 |
Income Statement
In the last 12 months, BIO.B had revenue of $2.59 billion and earned $222.40 million in profits. Earnings per share was $8.26.
| Revenue | 2.59B |
| Gross Profit | 1.35B |
| Operating Income | 272.30M |
| Pretax Income | 350.40M |
| Net Income | 222.40M |
| EBITDA | 441.00M |
| EBIT | 272.30M |
| Earnings Per Share (EPS) | $8.26 |
Balance Sheet
The company has $1.62 billion in cash and $1.37 billion in debt, with a net cash position of $248.10 million or $9.28 per share.
| Cash & Cash Equivalents | 1.62B |
| Total Debt | 1.37B |
| Net Cash | 248.10M |
| Net Cash Per Share | $9.28 |
| Equity (Book Value) | 7.17B |
| Book Value Per Share | 268.30 |
| Working Capital | 2.06B |
Cash Flow
In the last 12 months, operating cash flow was $492.60 million and capital expenditures -$139.50 million, giving a free cash flow of $353.10 million.
| Operating Cash Flow | 492.60M |
| Capital Expenditures | -139.50M |
| Depreciation & Amortization | 168.70M |
| Net Borrowing | -500,000 |
| Free Cash Flow | 353.10M |
| FCF Per Share | $13.21 |
Margins
Gross margin is 52.04%, with operating and profit margins of 10.52% and 8.59%.
| Gross Margin | 52.04% |
| Operating Margin | 10.52% |
| Pretax Margin | 13.53% |
| Profit Margin | 8.59% |
| EBITDA Margin | 17.03% |
| EBIT Margin | 10.52% |
| FCF Margin | 13.64% |
Dividends & Yields
BIO.B does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.11% |
| Shareholder Yield | 3.11% |
| Earnings Yield | 2.16% |
| FCF Yield | 3.43% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 1.26% |
| EPS Growth Forecast (3Y) | 0.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO.B has an Altman Z-Score of 3.19 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 5 |